Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
4 hedge funds and large institutions have $550K invested in Loncar China BioPharma ETF in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.
22% more capital invested
Capital invested by funds: $451K → $550K (+$98.9K)
0% more funds holding
Funds holding: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$113K |
| 2 |
GS
GTS Securities
New York
|
+$51K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $276K | +$113K | +7,357 | +61% |
|
|
GS
2
GTS Securities
New York
| $267K | +$51K | +3,334 | +22% |
|
|
BBPWM
3
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $4.39K | – | – | – |
|
4
Morgan Stanley
New York
| $2.68K | – | – | – |
|
CHNA Hedge Fund Activity: Q3 2023 in Review
4 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q3 2023, worth a combined $550K — up 22% from $451K a quarter earlier.
Fund positioning in CHNA was balanced in Q3 2023: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, adding an estimated $113K.
- 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $550K of Loncar China BioPharma ETF stock for Q3 2023, up 22% quarter-over-quarter.
- 0 funds opened new Loncar China BioPharma ETF positions in Q3 2023 and 0 closed out.
- The largest Loncar China BioPharma ETF buyer in Q3 2023 was Jane Street, an estimated $113K added.
Based on aggregated 13F filings for Q3 2023.